A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156252 Novel Stra6 polypeptides
10/24/2002	US20020156123 Novel pharmaceutical compositions for modulating angiogenesis
10/24/2002	US20020156119 Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
10/24/2002	US20020156118 Bis-indol-3-yl 3-pyrroline derivatives and paclitaxel
10/24/2002	US20020156116 Antiproliferative agents for disorders with GRB-2 adaptor protein function; treating diabetes, insulin resistance, insulin deficiency and insulin allergy
10/24/2002	US20020156113 Farnesyl transferase inhibitors; anticancer agents
10/24/2002	US20020156112 Endostatin-like angiogenesis inhibition
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156107 Amino ceramide - like compounds and therapeutic methods of use
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156090 Estrogen agonist/antagonist to prevente myocardial infarction or stroke, maintaining or improving vascular reactivity, treat renal failure, peripheral arterial occlusive disease, coronary artery disease, or raynaud's phenomenon
10/24/2002	US20020156083 3-hetero-arylidene-2-indolinone compounds; anticancer agents
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156077 Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives
10/24/2002	US20020156074 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors
10/24/2002	US20020156071 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
10/24/2002	US20020156069 Benzo thiadiazine matrix metalloproteinase inhibitors
10/24/2002	US20020156061 Administering to a mammal a matrix metalloproteinase inhibiting amount of derivatives of isophthalic acid, isophthalic acid ester or isothalamide compounds to treat cancer, rheumatic arthritis atherosclerosis and osteoporosis
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156041 Non-squamous epithelium-specific transcription
10/24/2002	US20020156040 Antisense oligonucleotides that bind to the enzyme's start codon; inhibiting enzymes such as superoxide dismutase
10/24/2002	US20020156035 NET-4 is a member of the tetraspan transmembrane receptor family; antisense molecules, ribozymes, antibodies and antibody fragments for reductin NET-4 gene expression or activity; antitumor agents
10/24/2002	US20020156030 Heterocyclic aromatic compounds and uses thereof
10/24/2002	US20020156024 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
10/24/2002	US20020156013 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
10/24/2002	US20020156005 m32404, a novel human trypsin and uses thereof
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155999 Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155992 Paclitaxel, epipodophyllotoxin, decetaxel, topotecan, and podophyllotoxin covalently conjugated to a polypeptide drug carrier having 50-90% by weight glutamic acid; inproved solubility
10/24/2002	US20020155988 Uses of transport proteins
10/24/2002	US20020155987 Isolated endostatin, especially approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII
10/24/2002	US20020155609 Monocyte-specific particulate delivery vehicle
10/24/2002	US20020155572 Peptide for use in diagnosis and treatment of alzheimier's disease
10/24/2002	US20020155534 SBHWSB2: a new member of the WD40 SOCS box family
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155527 Nucleotide sequences coding membrane protein for use in the treatment of tumors
10/24/2002	US20020155498 Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
10/24/2002	US20020155470 Intercalation compound for use in the diagnosis and detection of genetic disorders
10/24/2002	US20020155467 Detecting preferential polymorphism in sample; obtain nucleotide sequence sample, incubate with probe, detect signal, presence of signal indicates polymorphism
10/24/2002	US20020155452 Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors
10/24/2002	US20020155447 Nucleotide sequences coding polypeptide for use in the treatment of cancer
10/24/2002	US20020155184 Phytochemotherapy for cancer
10/24/2002	US20020155178 Compositions and methods for cancer prevention and treatment derived from Inula britannica
10/24/2002	US20020155144 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/24/2002	US20020155135 Method of making patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
10/24/2002	US20020155115 Cancer therapy
10/24/2002	US20020155111 For the vaccination of patients having malignant B cell diseases
10/24/2002	US20020155102 Administering to a mammal formulation of cationic lipids and a substance that affects angiogenesis; allowing formulation to associate with angiogenic endothelial cells of an angiogenic blood vesselsuch that it enters cells
10/24/2002	US20020155097 For therapy and prophylaxis of cancer and tumors
10/24/2002	US20020155089 Drug delivery systems for photodynamic therapy
10/24/2002	DE10113604A1 Verfahren zur Spaltung des humanen Wachstumshormons GH A process for cleavage of human growth hormone GH
10/24/2002	DE10113185A1 Zusammensetzung, enthaltend einen Gallium(III)-Komplex und einen therapeutisch wirksamen Platin-Komplex A composition comprising a gallium (III) complex and a therapeutically effective platinum complex
10/24/2002	CA2445990A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	CA2444842A1 Toluene sulfonamide-containing anti-tumor composition and method of use thereof
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444264A1 Prodrugs via acylation with cinnamate
10/24/2002	CA2444262A1 Bifunctional energy-reversible acyl-compositions
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2444164A1 Pufa polyketide synthase systems and uses thereof
10/24/2002	CA2443995A1 Endothelial cell expression patterns
10/24/2002	CA2443968A1 Diagnosis and treatment of cancer: i
10/24/2002	CA2443912A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto
10/24/2002	CA2443910A1 Novel use of arylethenesulfonamide derivatives
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443733A1 Peptide antiangiogenic drugs
10/24/2002	CA2443732A1 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	CA2443709A1 Novel cyclo azaphospha hydrocarbons
10/24/2002	CA2443705A1 Cyclic single strand trispecific antibody
10/24/2002	CA2443701A1 Triazinyl acrylamide derivatives as kinase inhibitors
10/24/2002	CA2443655A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443366A1 Triazinyl amide derivatives as angiogenesis inhibitors
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2443147A1 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
10/24/2002	CA2443141A1 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	CA2443123A1 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
10/24/2002	CA2443052A1 Use of cationic dextran derivatives for protecting dose-limiting organs
10/24/2002	CA2442729A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	CA2442264A1 A method of treating cancer
10/24/2002	CA2441274A1 Aurones as telomerase inhibitors
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251129A1 Pyrimidine derivatives having antitumor effect
10/23/2002	EP1251127A1 Novel sidechain-bearing taxanes and intermediates thereof
10/23/2002	EP1251125A2 New camptothecin analogues, preparation methods thereof, use thereof as drugs, and pharmaceutical compositions containing them
10/23/2002	EP1250934A1 Anticancer compositions
10/23/2002	EP1250933A1 Vaccines including as an adjuvant high dose type I IFN
10/23/2002	EP1250928A1 Cancer cell implantation inhibitors
10/23/2002	EP1250926A2 Use of a water-insoluble S-camptothecin with a closed lactone ring in the manufacture of a medicament for treatment of colon cancer
10/23/2002	EP1250455A1 Antisense inhibition of ptp1b expression
10/23/2002	EP1250434A2 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
10/23/2002	EP1250432A2 Nuclear hormone receptors
10/23/2002	EP1250425A2 Secreted human proteins, polynucleotides encoding them and methods of using the same
10/23/2002	EP1250422A2 Myeloid colony stimulating factor and uses thereof
10/23/2002	EP1250421A1 Recombinant flaviviruses and methods of use thereof
10/23/2002	EP1250355A1 Chimeric prostate-homing peptides with pro-apoptotic activity

1 ... 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 ... 2211